Gebski Christine
Known title: See RemarksCIK: 0001849585
Associated companies
Transaction History
| RGEN | ▼ Sell | Tax Withholding | 334 | $55K | 5/14/2024 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 386 | $76K | 3/7/2024 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 131 | $25K | 3/4/2024 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 461 | $89K | 3/4/2024 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 447 | $86K | 3/1/2024 | View on chart |
| RGEN | ▲ Buy | Grant | 391 | $0 | 2/29/2024 | View on chart |
| RGEN | ▼ Sell | Open Market | 3,788 | $557K | 11/10/2023 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 334 | $51K | 5/16/2023 | View on chart |
| RGEN | ▲ Buy | Grant | 375 | $0 | 3/3/2023 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 126 | $24K | 3/3/2023 | View on chart |
| RGEN | ▲ Buy | Grant | 3,467 | $0 | 3/2/2023 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 630 | $110K | 3/2/2023 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 460 | $80K | 2/28/2023 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 452 | $78K | 2/28/2023 | View on chart |
| RGEN | ▼ Sell | Open Market | 3,357 | $816K | 8/4/2022 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 335 | $50K | 5/13/2022 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 598 | $118K | 2/28/2022 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 462 | $91K | 2/27/2022 | View on chart |
| RGEN | ▲ Buy | Grant | 2,124 | $0 | 2/24/2022 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 181 | $34K | 2/24/2022 | View on chart |
| RGEN | ▲ Buy | Grant | 450 | $0 | 2/17/2022 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 224 | $41K | 2/17/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Repligen Completes BioLife Solutions Acquisition
Repligen has finalized its acquisition of BioLife Solutions, a move that follows shareholder approval of the merger. This transaction expands Repligen's portfolio in the biopharmaceutical sector. The stock recently reached a 52-week high, reflecting market interest in the company's growth strategy.
Repligen Completes BioLife Solutions Acquisition. Repligen has finalized its acquisition of BioLife Solutions, a move that follows shareholder approval of the merger. This transaction expands Repligen's portfolio in the biopharmaceutical sector. The stock recently reached a 52-week high, reflecting market interest in the company's growth strategy.